StockNews.com Initiates Coverage on TherapeuticsMD (NASDAQ:TXMD)

Equities researchers at StockNews.com initiated coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a report released on Sunday. The firm set a “hold” rating on the stock.

TherapeuticsMD Stock Performance

TXMD stock opened at $1.69 on Friday. TherapeuticsMD has a fifty-two week low of $1.43 and a fifty-two week high of $3.15. The company’s 50 day moving average price is $1.76 and its 200 day moving average price is $1.93.

TherapeuticsMD (NASDAQ:TXMD) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.09) earnings per share (EPS) for the quarter. The firm had revenue of $0.23 million during the quarter.

Hedge Funds Weigh In On TherapeuticsMD

Hedge funds have recently made changes to their positions in the company. ADAR1 Capital Management LLC acquired a new stake in shares of TherapeuticsMD in the 4th quarter valued at about $612,000. Prosperity Consulting Group LLC purchased a new stake in TherapeuticsMD in the first quarter valued at approximately $56,000. Finally, Clearline Capital LP boosted its holdings in shares of TherapeuticsMD by 18.9% in the second quarter. Clearline Capital LP now owns 636,622 shares of the company’s stock valued at $1,025,000 after acquiring an additional 101,282 shares during the period. Hedge funds and other institutional investors own 30.74% of the company’s stock.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.